Working in the space of Neurodegeneration and Autoimmune Disease with a particular focus on Alzheimers, Annexon Inc (NASDAQ:ANNX) is structured around providing novel disease modifying treatment for the related disorders - developing drugs that inhibit initiation of the classical complement pathway blocking downstream immune cell activities and membrane damage while leaving the lectin and alternative pathways intact. An alumni of JLabs South San Francisco, principals of the firm are working on development of therapeutics products to halt the progression of CMND. The firm's antibody pipeline is based on research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in triggering the loss of nerve connections and inducing inflammation in neurologic and ophthalmic disorders.
